Pulmonary arterial hypertension associated with congenital heart disease: An omics study

Maolin Zhao; Jian Liu; Mei Xin; Ke Yang; Honghao Huang; Wenxin Zhang; Jinbao Zhang; Siyi He

doi:10.3389/fcvm.2023.1037357

Pulmonary arterial hypertension associated with congenital heart disease: An omics study

Front Cardiovasc Med. 2023 Mar 10:10:1037357. doi: 10.3389/fcvm.2023.1037357. eCollection 2023.

Authors

Maolin Zhao¹, Jian Liu¹, Mei Xin¹, Ke Yang¹, Honghao Huang¹, Wenxin Zhang¹, Jinbao Zhang¹, Siyi He¹

Affiliation

¹ Department of Cardiovascular Surgery, Affiliated Hospital of Southwest Jiaotong University, General Hospital of Western Theater Command, Chengdu, China.

Abstract

Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a severely progressive condition with uncertain physiological course. Hence, it has become increasingly relevant to clarify the specific mechanisms of molecular modification, which is crucial to identify more treatment strategies. With the rapid development of high-throughput sequencing, omics technology gives access to massive experimental data and advanced techniques for systems biology, permitting comprehensive assessment of disease occurrence and progression. In recent years, significant progress has been made in the study of PAH-CHD and omics. To provide a comprehensive description and promote further in-depth investigation of PAH-CHD, this review attempts to summarize the latest developments in genomics, transcriptomics, epigenomics, proteomics, metabolomics, and multi-omics integration.

Keywords: biomarkers; congenital heart disease; molecular mechanism; omics; pulmonary arterial hypertension.

Publication types

Review

Grants and funding

This study is granted by the 2021 annal project of the General Hospital of Western Theater Command (grant no. 2021-XZYG-B31), Natural Science Foundation of Sichuan Province (grant no. 2022NSFSC1295).